GENEVA, SWITZERLAND--(Marketwire - April 24, 2008) - Addex Pharmaceuticals (SWISS: ADXN) announced that it has begun Phase I testing of two formulations of ADX10059 and that it will elaborate on ADX10059 development and its pipeline during today’s R&D day.
